FDA
-
-
-
-
-
-
-
Nuclear Power Surge, $10M Buyback, and a $1.9B SEO Bombshell
-
-
-
-
-
-
-
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
-
-
-
-
-
-
-
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
-
-
-
-
-
-
-
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
-
-
-
-
-
-
-
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

